Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Immune checkpoint blockade is revolutionizing therapy for advanced cancer, but many patients do not respond to treatment. The identification of robust biomarkers that predict clinical response to specific checkpoint inhibitors is critical in order to stratify patients and to rationally select combinations in the context of an expanding array of therapeutic options. METHODS: We performed multiparameter flow cytometry on freshly isolated metastatic melanoma samples from 2 cohorts of 20 patients each prior to treatment and correlated the subsequent clinical response with the tumor immune phenotype. RESULTS: Increasing fractions of programmed cell death 1 high/cytotoxic T lymphocyte-associated protein 4 high (PD-1hiCTLA-4hi) cells within the tumor-infiltrating CD8+ T cell subset strongly correlated with response to therapy (RR) and progression-free survival (PFS). Functional analysis of these cells revealed a partially exhausted T cell phenotype. Assessment of metastatic lesions during anti-PD-1 therapy demonstrated a release of T cell exhaustion, as measured by an accumulation of highly activated CD8+ T cells within tumors, with no effect on Tregs. CONCLUSIONS: Our data suggest that the relative abundance of partially exhausted tumor-infiltrating CD8+ T cells predicts response to anti-PD-1 therapy. This information can be used to appropriately select patients with a high likelihood of achieving a clinical response to PD-1 pathway inhibition. FUNDING: This work was funded by a generous gift provided by Inga-Lill and David Amoroso as well as a generous gift provided by Stephen Juelsgaard and Lori Cook.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the presence of CD8 + PD-1 hi T cells in the tumors of patients with melanoma and patients with NSCLC prior to anti-PD-1 administration was predictive of treatment response and correlated with overall survival (146, 147).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [146]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Self-citationPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Self-citationBrahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Cited by
Items 101–200 of 528
Okoye, I., Houghton, M., Tyrrell, D. L., Barakat, K., & Elahi, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01215 · Cited by 116
Russo, A., Franchina, T., Ricciardi, G. R. R., Battaglia, A., Scimone, A., Berenato, R., Giordano, A., & Adamo, V. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26609 · Cited by 111
Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
Versteven, M., den Bergh, J. M. J. V., Marcq, E., Smits, E., Tendeloo, V. F. V., Hobo, W. A., & Lion, E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00394 · Cited by 104
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
Paré, L., Pascual, T., Seguí, E., Teixidó, C., González‐Cao, M., Galván, P., Rodríguez, A., González‐Farré, B., Cuatrecasas, M., Pineda, E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy335 · Cited by 108
β-Catenin–mediated immune evasion pathway frequently operates in primary cutaneous melanomas
Nsengimana, J., Laye, J., Filia, A., O’Shea, S., Muralidhar, S., Poźniak, J., Droop, A., Chan, M., Walker, C., Parkinson, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95351 · Cited by 96
Ottonello, S., Genova, C., Cossu, I., Fontana, V., Rijavec, E., Rossi, G., Biello, F., Bello, M. G. D., Tagliamento, M., Alama, A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00125 · Cited by 100
NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma
Brennan, K., Shin, J. H., Tay, J. K., Prunello, M., Gentles, A. J., Sunwoo, J. B., & Gevaert, O. (2017) · Scientific Reports · doi:10.1038/s41598-017-17298-x · Cited by 96
CTLA4 methylation predicts response to anti–PD-1 and anti–CTLA-4 immunotherapy in melanoma patients
Goltz, D., Gevensleben, H., Vogt, T. J., Dietrich, J., Golletz, C., Bootz, F., Kristiansen, G., Landsberg, J., & Dietrich, D. (2018) · JCI Insight · doi:10.1172/jci.insight.96793 · Cited by 96
Huang, X., Hu, M., Sun, T., Li, J., Zhou, Y., Yan, Y., Xuan, B., Wang, J., Xiong, H., Ji, L., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.10.005 · Cited by 104
Ratti, C., Botti, L., Cancila, V., Galvan, S., Torselli, I., Garofalo, C., Manara, M. C., Bongiovanni, L., Valenti, C. F., Burocchi, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3186 · Cited by 90
Presti, D., Dall’Olio, F. G., Besse, B., Ribeiro, J. M., Meglio, A. D., & Soldato, D. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103773 · Cited by 99
da Silva, I. P., Ahmed, T., McQuade, J. L., Nebhan, C. A., Park, J., Versluis, J. M., Serra-Bellver, P., Khan, Y., Slattery, T., Oberoi, H. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01701 · Cited by 97
Bridge, J. A., Lee, J., DAUD, A. I., Wells, J. W., & Bluestone, J. A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00351 · Cited by 89
Self-citationde Rodas, M. L., Villalba-Esparza, M., Sanmamed, M. F., Chen, L., Rimm, D. L., & Schalper, K. A. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00984-x · Cited by 109
Beckermann, K. E., Jolly, P. C., Kim, J. Y., Bordeaux, J., Puzanov, I. J., Rathmell, W. K., & Johnson, D. B. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0206-1 · Cited by 87
Yu, H., Chen, Z., Ballman, K. V., Watson, M. A., Govindan, R., Lanc, I., Beer, D. G., Bueno, R., Chirieac, L. R., Chui, M. H., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.006 · Cited by 92
Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy
Loo, K. L., Tsai, K. K., Mahuron, K. M., Liu, J., Pauli, M. L., Sandoval, P. M., Nosrati, A., Lee, J., Chen, L., Hwang, J. J., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93433 · Cited by 86
Self-citationTietze, J. K., Angelova, D., Heppt, M. V., Reinholz, M., Murphy, W. J., Spannagl, M., Ruzicka, T., & Berking, C. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.031 · Cited by 94
A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma
Hsu, F.-S., Su, C.-H., & Huang, K.-H. (2017) · Journal of Immunology Research · doi:10.1155/2017/6940546 · Cited by 86
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
Xiao, Q., Nobre, A., Piñeiro, P., Berciano‐Guerrero, M., Alba, E., Cobo, M., Lauschke, V. M., & Barragán, I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010286 · Cited by 84
Malvehy, J., Самойленко, И. В., Schadendorf, D., Gutzmer, R., Grob, J., Sacco, J. J., Gorski, K. S., Anderson, A., Pickett, C. A., Liu, K., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001621 · Cited by 89
Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
Li, X., Song, W., Shao, C., Shi, Y., & Han, W. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0086-z · Cited by 82
Immunotherapy for advanced thyroid cancers — rationale, current advances and future strategies
French, J. D. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0398-9 · Cited by 86
Xu, C., Zhang, Y., Rolfe, P. A., Hernández, V. M., Guzman, W., Kradjian, G., Marelli, B., Qin, G., Qi, J., Wang, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0483 · Cited by 75
Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges
McKean, W. B., Moser, J. C., Rimm, D. L., & Hu‐Lieskovan, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280571 · Cited by 79
Singh, M. P., Sethuraman, S. N., Miller, C., Malayer, J. R., & Ranjan, A. (2020) · Theranostics · doi:10.7150/thno.49517 · Cited by 82
Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer
Hsieh, C.-H., Jian, C.-Z., Lin, L., Low, G.-S., Ou, P.-Y., Hsu, C., & Ou, D. (2022) · Cancers · doi:10.3390/cancers14020294 · Cited by 73
Guillebon, É. D., Dardenne, A., Saldmann, A., Séguier, S., Tran, T., Paolini, L., Lebbé, C., & Tartour, É. (2020) · International Journal of Cancer · doi:10.1002/ijc.32889 · Cited by 78
Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma
Magnes, T., Wagner, S. M., Kiem, D., Weiß, L., Rinnerthaler, G., Greil, R., & Melchardt, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094981 · Cited by 82
Sanborn, R. E., Pishvaian, M. J., Callahan, M. K., Weise, A. M., Sikic, B. I., Rahma, O. E., Cho, D. C., Rizvi, N. A., Sznol, M., Lutzky, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005147 · Cited by 78
Pulanco, M. C., Madsen, A. T., Tanwar, A., Corrigan, D. T., & Zang, X. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01019-8 · Cited by 75
Nam, S., Lee, A., Lim, J., & Lim, J.-S. (2019) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2018.201 · Cited by 68
Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
Zemek, R. M., Chin, W. L., Nowak, A. K., Millward, M., Lake, R., & Lesterhuis, W. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00223 · Cited by 75
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
Shklovskaya, E., & Rizos, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136741 · Cited by 78
Pachynski, R. K., Wang, P., Salazar, N., Zheng, Y., Nease, L. A., Rosalez, J., Leong, W.-I., Virdi, G., Rennier, K. R., Shin, W. J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00983 · Cited by 74
Chen, H., Yang, M., Wang, Q., Song, F., Li, X., & Chen, K. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1608132 · Cited by 88
Memarnejadian, A., Meilleur, C. E., Shaler, C. R., Khazaie, K., Bennink, J. R., Schell, T. D., & Haeryfar, S. M. M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700643 · Cited by 62
Melanoma and Vitiligo: In Good Company
Failla, C. M., Carbone, M. L., Fortes, C., Pagnanelli, G., & D’Atri, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225731 · Cited by 69
Toulmonde, M., Lucchesi, C., Verbeke, S., Crombé, A., Adam, J., Geneste, D., Chaire, V., Laroche‐Clary, A., Perret, R. E., Bertucci, F., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103131 · Cited by 68
Machiraju, D., Wiecken, M., Lang, N., Hülsmeyer, I., Roth, J., Schank, T. E., Eurich, R., Halama, N., Enk, A., & Hassel, J. C. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1926762 · Cited by 72
Shoushtari, A. N., Olszanski, A. J., Nyakas, M., Hornyak, T. J., Wolchok, J. D., Levitsky, V., Kuryk, Ł., Hansen, T. B., & Jaderberg, M. E. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2046 · Cited by 70
Wang, C., Gong, J., Tu, T. Y., Lee, P. P., & Fakih, M. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.01.09 · Cited by 62
Hargadon, K. M. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.37 · Cited by 67
Borcherding, N. C., Kolb, R. H., Gullicksrud, J. A., Vikas, P., Zhu, Y., & Zhang, W. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.030 · Cited by 69
Layilin augments integrin activation to promote antitumor immunity
Mahuron, K. M., Moreau, J. M., Glasgow, J. E., Boda, D. P., Pauli, M. L., Gouirand, V., Panjabi, L., Grewal, R., Luber, J. M., Mathur, A. N., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20192080 · Cited by 59
Self-citationKverneland, A. H., Enevold, C., Donia, M., Bastholt, L., Svane, I. M., & Nielsen, C. H. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1424674 · Cited by 60
Herbreteau, G., Vallée, A., Knol, A., Théoleyre, S., Quereux, G., Varey, É., Khammari, A., Dréno, B., & Denis, M. G. (2018) · Oncotarget · doi:10.18632/oncotarget.25404 · Cited by 65
Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies
Filipović, A., Miller, G., & Bolen, J. B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00155 · Cited by 64
Molecular predictors of response to pembrolizumab in thymic carcinoma
He, Y., Ramesh, A., Gusev, Y., Bhuvaneshwar, K., & Giaccone, G. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100392 · Cited by 67
Petitprez, F., Sun, C., Lacroix, L., Sautès‐Fridman, C., de Reyniès, A., & Fridman, W. H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00390 · Cited by 65
Emerging biomarkers for cancer immunotherapy in melanoma
Axelrod, M. L., Johnson, D. B., & Balko, J. M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.004 · Cited by 61
Pagadala, M. S., Sears, T. J., Wu, V. H., Pérez‐Guijarro, E., Kim, H., Castro, A., Talwar, J. V., González-Colín, C., Cao, S., Schmiedel, B. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38271-5 · Cited by 66
Salama, A. K. S., & Moschos, S. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw534 · Cited by 57
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Yan, X., Zhang, S., Deng, Y., Wang, P., Hou, Q., & Xu, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01050 · Cited by 57
Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment
Wong, Y. N. S., Joshi, K., Khetrapal, P., Ismail, M., Reading, J. L., Sunderland, M. W., Georgiou, A., Furness, A. J. S., Ben Aissa, A., Ghorani, E., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20181003 · Cited by 57
Wawrzyniak, P., & Hartman, M. L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02294-x · Cited by 72
Characterization and Comparison of GITR Expression in Solid Tumors
Vence, L. M., Bucktrout, S. L., Curbelo, I. F., Blando, J. M., Smith, B. M., Mahne, A. E., Lin, J. C.-Y., Park, T., Pascua, E., Sai, T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0289 · Cited by 58
A Four-Factor Immunoscore System That Predicts Clinical Outcome for Stage II/III Gastric Cancer
Wen, T., Wang, Z., Li, Y., Li, Z., Che, X., Fan, Y., Wang, S., Qu, J., Yang, X., Hou, K., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0381 · Cited by 58
Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma
Lee, H.-S., Jang, H.-J., Choi, J. M., Zhang, J., de Rosen, V. L., Wheeler, T. M., Lee, J.-S., Tu, T., Jindra, P. T., Kerman, R. H., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98575 · Cited by 55
Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors
Gibellini, L., Biasi, S. D., Porta, C., Tartaro, D. L., Depenni, R., Pellacani, G., Sabbatini, R., & Cossarizza, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00490 · Cited by 56
Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data
Wassmer, C., Hajji, S. E., Papazarkadas, X., Compagnon, P., Tabrizian, P., Lacotte, S., & Toso, C. (2023) · Cancers · doi:10.3390/cancers15184574 · Cited by 57
Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy
Mukhopadhyay, A., Wright, J. H., Shirley, S. A., Canton, D. A., Burkart, C., Connolly, R. J., Campbell, J. S., & Pierce, R. H. (2018) · Gene Therapy · doi:10.1038/s41434-018-0044-5 · Cited by 59
Self-citationT cell costimulation, checkpoint inhibitors and anti-tumor therapy
Nandi, D., Pathak, S., Verma, T., Singh, M., Chattopadhyay, A., Thakur, S., Raghavan, A., Gokhroo, A., & Vijayamahantesh, V. (2020) · Journal of Biosciences · doi:10.1007/s12038-020-0020-2 · Cited by 61
Kean, L. S., Turka, L. A., & Blazar, B. R. (2017) · Immunological Reviews · doi:10.1111/imr.12523 · Cited by 52
Tumor Vaccines for Malignant Gliomas
Srinivasan, V. M., Ferguson, S. D., Lee, S., Weathers, S.-P. S., Kerrigan, B. C. P., & Heimberger, A. B. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0522-2 · Cited by 51
Kato, R., Yamasaki, M., Urakawa, S., Nishida, K., Makino, T., Morimoto-Okazawa, A., Kawashima, A., Iwahori, K., Suzuki, S., Ueda, R., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2225-x · Cited by 56
Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma
Cristina, V., Gómez, R. G. H., Szturz, P., Espeli, V. G., & Siano, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215399 · Cited by 55
Liu, J., Sun, B., Guo, K., Yang, Z., Zhao, Y., Gao, M., Yin, Z., Jiang, K., Dong, C., Gao, Z., et al. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00510-0 · Cited by 58
Wang, X., Luo, X., Xiao, R., Liu, X., Zhou, F., Jiang, D., Bai, J., Cui, M., You, L., & Yupei, Z. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02334-4 · Cited by 65
Impact of the microbiome on cancer progression and response to anti-cancer therapies
Rosean, C. B., Feng, T.-Y., Azar, F. N., & Rutkowski, M. R. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.005 · Cited by 55
PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
Wang, Y., & Li, G. (2019) · Frontiers of Medicine · doi:10.1007/s11684-018-0674-4 · Cited by 56
Jílková, Z. M., Aspord, C., Kurma, K., Granon, A., Sengel, C., Stürm, N., Marche, P. N., & Decaens, T. (2019) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000058 · Cited by 55
Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies
Ngiow, S. F., & Young, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01633 · Cited by 54
Masterful Antibodies: Checkpoint Blockade
Lönberg, N., & Korman, A. J. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0057 · Cited by 52
Moore, T. V., Wagner, C. R., Scurti, G. M., Hutchens, K. A., Godellas, C. V., Clark, A. L., Kolawole, E. M., Hellman, L. M., Singh, N. K., Huyke‐Hernández, F. A., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2073-0 · Cited by 50
Niemeijer, A.-L. N., Sahba, S., Smit, E. F., Lissenberg-Witte, B. I., Langen, A. J. D., & Thunnissen, E. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0888-5 · Cited by 54
Signorelli, D., Giannatempo, P., Grazia, G., Aiello, M. M., Bertolini, F., Mirabile, A., Buti, S., Vasile, E., Scotti, V., Pisapia, P., et al. (2019) · BioMed Research International · doi:10.1155/2019/9056417 · Cited by 51
Li, P., Qin, P., Fu, X., Zhang, G., Yan, X., Zhang, M., Zhang, X., Yang, J., Wang, H., & Ma, Z. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-163 · Cited by 49
Association between tumor mutation burden and immune infiltration in ovarian cancer
Fan, S., Gao, X., Qin, Q., Li, H., Yuan, Z., & Zhao, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107126 · Cited by 57
Wang, J., Siu, M. K.-Y., Jiang, Y., Leung, T. H.-Y., Chan, D. W., Wang, H., Ngan, H., & Chan, K. K. L. (2021) · Biomolecules · doi:10.3390/biom11121749 · Cited by 48
Huang, Y., Nahar, S., Alam, M. M., Hu, S., McVicar, D. W., & Yang, D. (2023) · ACS Nano · doi:10.1021/acsnano.3c03195 · Cited by 46
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
Bucktrout, S. L., Bluestone, J. A., & Ramsdell, F. (2018) · Genome Medicine · doi:10.1186/s13073-018-0588-4 · Cited by 50
Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma
Shklovskaya, E., Lee, J., Lim, S. Y., Stewart, A., Pedersen, B., Ferguson, P. M., Saw, R. P. M., Thompson, J. F., Shivalingam, B., Carlino, M. S., et al. (2020) · Cancers · doi:10.3390/cancers12113374 · Cited by 49
Carlisle, J. W., Jansen, C. S., Cardenas, M. A., Sobierajska, E., Reyes, A. M., Greenwald, R., del Balzo, L., Prokhnevska, N., Küçük, Ö., Carthon, B. C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004803 · Cited by 46
Radiation and Immune Checkpoint Blockade: From Bench to Clinic
Shabason, J. E., & Minn, A. J. (2017) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2017.03.002 · Cited by 45
IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment
Munn, D. H., Sharma, M. D., Johnson, T. S., & Rodríguez, P. C. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2010-2 · Cited by 45
Xu, X., Guo, Q., Cui, C., Lin, Y., Zhang, L. J., Ding, X., Li, Q., Wang, M., Yang, W., Kong, Y., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00197-2 · Cited by 51
Current and emerging systemic therapies for cutaneous metastatic melanoma
Mason, R., Au, L., Garces, A. I., & Larkin, J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1601700 · Cited by 46
Metabolic dynamics instruct CD8 + T‐cell differentiation and functions
Bevilacqua, A., Li, Z., & Ho, P. (2022) · European Journal of Immunology · doi:10.1002/eji.202149486 · Cited by 42
Luo, C., Zhang, R., Guo, R., Wu, L., Xue, T., He, Y., Jin, Y., Zhao, Y., Zhang, Z., Zhang, P., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.02.007 · Cited by 38
Full spectrum flow cytometry and mass cytometry: A 32‐marker panel comparison
Jaimes, M. C., Leipold, M. D., Kraker, G., Amir, E.-A. D., Maecker, H. T., & Lannigan, J. A. (2022) · Cytometry Part A · doi:10.1002/cyto.a.24565 · Cited by 44
Wong, C. W., Evangelou, C., Sefton, K. N., Leshem, R., Zhang, W., Gopalan, V., Chattrakarn, S., Carro, M. L. F., Uzuner, E., Mole, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41737-1 · Cited by 48
Pan, Q., Zhao, J., Liu, L., Zhang, D., Wang, L., Hu, W., Weng, D., Xu, X. M., Li, Y., Tang, Y., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01788-2 · Cited by 42
Harding, J. J., Khalil, D. N., & Abou‐Alfa, G. K. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05517-6 · Cited by 42
Zhang, S., Bai, X., & Shan, F. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106247 · Cited by 43
Akbari, H., Taghizadeh‐Hesary, F., & Bahadori, M. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.12.001 · Cited by 38
Immunotherapy for Gestational Trophoblastic Neoplasia: A New Paradigm
Baas, I. O., Westermann, A. M., You, B., Bolze, P., Seckl, M. J., & Ghorani, E. (2023) · Gynecologic and Obstetric Investigation · doi:10.1159/000533972 · Cited by 39
Hepatocytes coordinate immune evasion in cancer via release of serum amyloid A proteins
Stone, M. L., Lee, J., Lee, J. W., Coho, H., Tariveranmoshabad, M., Wattenberg, M. M., Choi, H., Herrera, V. M., Xue, Y., Choi-Bose, S., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01820-1 · Cited by 42
Tsuchiya, N., Zhang, R., Iwama, T., Ueda, N., Liu, T., Tatsumi, M., Sasaki, Y., Shimoda, R., Osako, Y., Sawada, Y., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.086 · Cited by 40
Capone, M., Fratangelo, F., Giannarelli, D., Sorrentino, C., Turiello, R., Zanotta, S., Galati, D., Madonna, G., Tuffanelli, M., Scarpato, L., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02285-0 · Cited by 39
Metadata
- Authors
- Daud, A. I., Loo, K., Pauli, M. L., Sanchez-Rodriguez, R., Sandoval, P. M., Taravati, K., Tsai, K., Nosrati, A., Nardo, L., Alvarado, M. D., Algazi, A. P., Pampaloni, M. H., Lobach, I. V., Hwang, J., Pierce, R. H., Gratz, I. K., Krummel, M. F., & Rosenblum, M. D.
- Affiliations
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- University of California, San Francisco (US)
- University of Salzburg (AT)
- Corresponding author
- Rosenblum, Michael D.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2016-08-15
- Volume
- 126
- Issue
- 9
- Pages
- 3447-3452
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5004965
- OpenAlex
- W2512255557
- Cited by
- 525
- References
- 23
- Citations by year
- 2026: 17 · 2025: 28 · 2024: 37 · 2023: 47 · 2022: 51 · 2021: 55 · 2020: 89 · 2019: 61 · 2018: 71 · 2017: 64 · 2016: 5
- FWCI
- 36.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- International Business Machines Corporation
- National Institutes of Health (1dp2ar068130-01)
- University of California, San Francisco
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (DP2-AR068130, R21AR066821, K08AR062064)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- metastatic melanoma, anti-PD-1 therapy, immune checkpoint blockade, tumor immune profiling, CD8+ T cell exhaustion, tumor-infiltrating lymphocytes, predictive biomarkers, treatment response prediction, progression-free survival, regulatory T cells
- MeSH terms
- Biopsy, Female, Flow Cytometry, Humans, Immune System, Lymphocyte Activation, Male, Melanoma, Neoplasm Metastasis, Phenotype, Skin Neoplasms, Cohort Studies, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, Leukocyte Common Antigens, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Tumor Microenvironment, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.